相关实验视频

Updated: Sep 14, 2025

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

基于血小板膜的生物模拟聚-CeO纳米酶复合物:用于综合性动脉样硬化治疗的宽频抗氧化系统

Yao Chen^1,2, Qingfa Tang^1,2, Qinglan Zhu^1,2

¹Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, People's Republic of China.

ACS applied materials & interfaces

|July 21, 2025

概括

一种新的纳米酶复合体,SS-CeO2@PLTM,通过向斑块和减少氧化应激,有效治疗动脉样硬化. 这种仿生系统改善了脂质代谢,并减少了小鼠的斑块大小,显示了心血管疾病管理的前景.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
心血管研究研究心血管研究

背景情况:

动脉样硬化 (AS) 的发病包括氧化压力,使抗氧化疗法成为潜在的治疗策略.
现有的抗氧化剂,如酸A (SAA) 和B (SAB) 有限制,包括短半衰期和不稳定性.
需要先进的治疗系统来克服这些限制,以有效治疗AS.

研究的目的:

开发一种生物模拟的血小板膜涂层的多二氧化纳米酶复合物 (SS-CeO2@PLTM) 用于向性动脉样硬化治疗.
评估SS-CeO2@PLTM.的广泛抗氧化活性和治疗疗效.
评估生物安全性和多因素心血管疾病管理的潜力.

主要方法:

通过SAA和SAB对二氧化的结合合成SS-CeO2@PLTM,随后进行生物模拟血小板膜涂层.
使用光谱 (UV-vis,FT-IR,XPS),显微镜 (TEM-EDS),FRET,分子模拟和释放试验进行表征.
在RAW264.7细胞的体外测定和在apoE-/-小鼠的体内研究中评估抗氧化,抗炎和减少斑块的影响.

主要成果:

证实SS-CeO2@PLTM的成功合成和pH响应释放.
证明了广泛的抗氧化活性,清除各种活性氧物种并增强内源性抗氧化酶.
有效向动脉样硬化斑块,显著减轻氧化应激,改善脂质新陈代谢,减少炎症,并在体内减少斑块面积.
通过血液溶解和体内试验验证了生物安全性.

结论:

通过解决氧化应激和炎症,SS-CeO2@PLTM在向动脉样硬化治疗中表现出卓越的疗效.
生物模拟纳米酶复合体为全面的心血管疾病管理提供了一个有前途的平台.
这项研究在治疗多因素心血管疾病方面提出了新的范式转变.

关键词:

动脉样硬化动脉样硬化纳米酶复合体是一个纳米酶复合体.氧化应激是一种氧化应激.血小板膜覆盖的纳米粒子聚醇是一种多醇.有针对性的交付目标.

更多相关视频

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...